Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The Company’s segments include Animal health, and Human health. The company has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The firm's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.